OPINION "By her hand," intones former handmaid June. She is messing with the biblical language of the tyrannical patriarchal theocracy of the Republic of Gilead – "By His hand", "Under His eye" - as …
→ Google Traduction
NORTHAMPTON, MA / ACCESSWIRE / September 30, 2022 / Kelly was getting ready to leave on a trip to celebrate her 25th wedding anniversary when she started experiencing pain in her abdomen and discovered a lump on her neck. When the pain progressed to the point where it got worse when she laid down, she asked her husband, an emergency room doctor, what he thought. After a few phone calls to his colleagues working in oncology, they went to see a lymphoma specialist and Kelly underwent a CAT scan the day before her trip. The doctor called Kelly and her husband during their vacation and said they needed to talk when she got back. Kelly says she "just knew" it was cancer. When she returned from the trip, she was diagnosed with stage four non-Hodgkin lymphoma. "It was earth shattering. Your whole world comes crashing down," she explains. "When cancer hits, nothing else matters." Kelly received six rounds of chemotherapy - one round every three weeks. But shortly after the chemo treatments ended, her pain returned.
→ Google Traduction
This year will probably go down as the roughest year for investors since the financial recession in 2008. The S&P 500 has shed more than 20% of its value year-to-date as inflation and interest rates weigh down the equities market. Hence, investors are scrambling to streamline their portfolios. In doing so, they might want to think about some biotech stocks to sell. Biotech stocks have typically been among the most risky investments. These firms spend a ton of money on research and development and offer little to no assurance that their pipeline will ever reach the commercialization stage. Additionally, most of these companies operate at a loss for years, which has irked investors of late. Hence, it’s probably best to sell off many of the non-performing biotech stocks before more significant losses arrive. That said, it’s true that the industry is set for incredible growth over the long term. The trick for investors is to perform extensive due diligence before wagering on biotech stocks.
→ Google Traduction
The United States'' lactose-free cheese brands specifically target allergy sufferers. Twenty years ago, Americans with allergies or intolerances, such as lactose intolerance, were the primary target market for American businesses. Expectations were low and the flavour of plant-based dairy substitutes was distinctive. NEWARK, DE / ACCESSWIRE / September 29, 2022 / According to FMI, the global lactose-free cheese market size is expected to reach a valuation of US$ 676.3 Mn by the end of 2022. The market is set to accelerate at a CAGR of 8.4% during 2022-2032. It is anticipated to be valued at US$ 1,515.1 Mn in 2032. FMI further states that around 35% of the global population was lactose intolerant, and 28% had dairy sensitivity or allergy in 2020. These figures are expected to grow at a fast pace in the evaluation period. It is further projected to result in consumers opting for lactose-free, dairy-free, and plant-based food products, including plant-based protein. This has boosted the demand and consumption of lactose-free cheese around the globe.
→ Google Traduction
Gilead Sciences, Inc. (Nasdaq: GILD) today announced updates to the World Health Organization’s (WHO) Therapeutics and COVID-19: living guideline.
→ Google Traduction
The best safe monthly dividend stocks are remarkably compelling during the current market downturn. However, many top dividend stocks have also taken a sizeable hit in value over the past several months. The pull-back presents an incredible opportunity to load up on dividend stocks and generate regular income. Dividend stocks usually belong to companies with stable businesses with robust earnings that can be reinvested for the benefit of their shareholders. During the current bear run, it can help investors cut down on their losses significantly. When the economy is in shambles, investors are looking for stocks to protect their portfolios. These stocks essentially pay investors to hold on to them and can potentially reinvest their income to supercharge portfolio growth. With that being said, let’s look at seven of the best dividend stocks you should invest in. EPR EPR Properties $37.43 GILD Gilead Sciences $63.93 CVX Chevron $145.78 SJT San Juan Basin Royalty Trust $9.85 INTC Intel $27.13 DOW Dow $45.05 LTC LTC Properties $37.18 EPR Properties ( EPR ) Source: Shutterstock Dividend Yield : 8.2% EPR Properties (NYSE: EPR ) has recently seen its stock dip due to rising interest rates.
→ Google Traduction
In the latest trading session, 0.96 million General Mills Inc. (NYSE:GIS) shares changed hands as the company’s beta touched 0.30. With the company’s most recent per share price at $78.12 changing hands around $0.15 or 0.20% at last look, the market valuation stands at $47.22B. GIS’s current price is a discount, trading about -3.99% off … The Stock Of General Mills Inc. (NYSE: GIS) Was Forecast By Analysts To Close At $88.00 Per Share By 2022. Read More »
→ Google Traduction
FOSTER CITY, CA / ACCESSWIRE / September 28, 2022 / Gilead Sciences, Inc. (Nasdaq:GILD) today announced updates to the World Health Organization''s (WHO) Therapeutics and COVID-19: living guideline , which now conditionally recommends Veklury® (remdesivir) for the treatment of patients with severe COVID-19 and continues to conditionally recommend Veklury in those with non-severe COVID-19 at the highest risk of hospitalization. The WHO conditional recommendation for Veklury''s use in the treatment of patients with severe COVID-19 is mainly driven by the final results of the WHO-sponsored SOLIDARITY study, which showed a statistically significant 17% lower relative risk of death or progression to needing ventilation in patients requiring supplemental oxygen at baseline, compared to standard of care (RR: 0.83; 95% CI: 0.75-0.93). Additionally, SOLIDARITY showed a statistically significant 13% lower relative risk of mortality with Veklury treatment for those patients hospitalized on supplemental oxygen and not requiring mechanical ventilation, compared with standard of care (RR: 0.87; 95% CI: 0.76-0.99).
→ Google Traduction
Merck & Company, Inc. found using ticker (MRK) now have 20 analysts in total covering the stock. The consensus rating is ''Buy''. The target price ranges between 125 and 85 calculating the average target price we see 100.85. Given that the stocks previous close was at 86.18 this would imply there is a potential upside of 17.0%. The day 50 moving average is 88.67 and the 200 day MA is 84.8. The company has a market capitalisation of $217,457m. Find out more information at: https://www.merck.com [stock_market_widget type="chart" template="basic" color="green" assets="MRK" range="6mo" interval="1d" axes="true" cursor="true" api="yf"] The potential market cap would be $254,473m based on the market concensus. Merck & Co., Inc. operates as a healthcare company worldwide. It operates through two segments, Pharmaceutical and Animal Health. The Pharmaceutical segment offers human health pharmaceutical products in the areas of oncology, hospital acute care, immunology, neuroscience, virology, cardiovascular, and diabetes, as well as vaccine products, such as preventive pediatric, adolescent, and adult vaccines.
→ Google Traduction
General Mills with ticker code (GIS) have now 17 analysts in total covering the stock. The consensus rating is ''Hold''. The target price ranges between 88 and 63 and has a mean target at 76.88. Given that the stocks previous close was at 78.66 this now indicates there is a potential downside of -2.3%. There is a 50 day moving average of 76.23 and the 200 day MA is 70.66. The market capitalisation for the company is $46,278m. Visit the company website at: https://www.generalmills.com [stock_market_widget type="chart" template="basic" color="green" assets="GIS" range="6mo" interval="1d" axes="true" cursor="true" api="yf"] The potential market cap would be $45,231m based on the market concensus. General Mills manufactures and markets branded consumer foods worldwide. The company operates in five segments: North America Retail; Convenience Stores & Foodservice; Europe & Australia; Asia & Latin America; and Pet. It offers ready-to-eat cereals, refrigerated yogurt, soup, meal kits, refrigerated and frozen dough products, dessert and baking mixes, bakery flour, frozen pizza and pizza snacks, snack bars, fruit and salty snacks, ice cream, nutrition bars, wellness beverages, and savory and grain snacks, as well as various organic products, including frozen and shelf-stable vegetables.
→ Google Traduction
GrubMarket, which offers software and operates an e-commerce platform connecting farmers and other food suppliers with customers, said it’s valued at more than $2 billion after raising $120 million in equity from new backers including General Mills Inc.’s venture arm.
→ Google Traduction
General Mills (NYSE:GIS) declares $0.54/share quarterly dividend, in line with previous.Forward yield 2.75%Payable Nov. 1; for shareholders of record Oct. 10; ex-div Oct.
→ Google Traduction
MINNEAPOLIS--(BUSINESS WIRE)--The General Mills Board of Directors has declared a quarterly dividend at the prevailing rate of $0.54 per share, payable November 1, 2022, to shareholders of record as of October 10, 2022. General Mills (NYSE: GIS) and its predecessor company have paid dividends without interruption for 124 years. About General Mills General Mills makes food the world loves. The company is guided by its Accelerate strategy to drive shareholder value by boldly building its brands,
→ Google Traduction
These are seven of the best stocks to buy that can see substantial returns in the months ahead. Despite the ongoing worries on Wall Street, seasoned investors realize that there may be a bull market in some segments of the market even during these gloomy weeks. Fears of sticky inflation and recession led to many investors reevaluating their investments or pulling their money out of the stock markets altogether. As a result, the S&P 500 index has dropped 23% year to date, while the tech-heavy NASDAQ 100 has lost close to a third of its value. However, for investors who research further, there is always a chance to find the best stocks to buy in a hidden bull market. Including several of those shares could help boost the performance of investment portfolios despite the overall market chaos. Even in 2022, with interest rates hitting a 14-year high in the U.S. and stocks getting hammered, we are experiencing localized bull markets in the energy and utility sectors. For instance, the energy sector, overall, has returned around 18% since January.
→ Google Traduction
Merck & Company with ticker code (MRK) now have 20 analysts covering the stock with the consensus suggesting a rating of ''Buy''. The target price ranges between 125 and 85 with a mean TP of 100.85. Given that the stocks previous close was at 87.51 this now indicates there is a potential upside of 15.2%. There is a 50 day moving average of 88.84 while the 200 day moving average is 84.74. The market capitalisation for the company is $219,838m. Visit the company website at: https://www.merck.com [stock_market_widget type="chart" template="basic" color="green" assets="MRK" range="6mo" interval="1d" axes="true" cursor="true" api="yf"] The potential market cap would be $253,350m based on the market concensus. Merck & Co. operates as a healthcare company worldwide. It operates through two segments, Pharmaceutical and Animal Health. The Pharmaceutical segment offers human health pharmaceutical products in the areas of oncology, hospital acute care, immunology, neuroscience, virology, cardiovascular, and diabetes, as well as vaccine products, such as preventive pediatric, adolescent, and adult vaccines.
→ Google Traduction
New Jersey, NJ -- ( SBWIRE ) -- 09/26/2022 -- The Latest research study released by HTF MI "Global (United States, European Union and China) Frozen Drinks Market Growth (Status and Outlook) 2022-2028" with 100+ pages of analysis on business Strategy taken up by key and emerging industry players and delivers know how of the current market trends, landscape, sales, drivers, opportunities, market viewpoint and status (2022-2028). The market Study is segmented by key a region that is accelerating the marketization. This section also provides the scope of different segments and applications that can potentially influence the market in the future. The detailed information is based on current trends and historic milestones. Some of the Major Companies covered in this Research are Coca Cola, RedBull, DESHI, Kraft Foods, Nestle, Pepsico, ABInbev, Unilever, Heineken Brouwerijen, LACTALIS, Asahi, Diageo, General Mills, Tsingtao, Mengniu & Yili etc. Click here for free sample + related graphs of the report @: https://www.htfmarketreport.com/sample-report/1910910-global-united-states-european-union-and-china-frozen-drinks-market Browse market information, tables and figures extent in-depth TOC on "Frozen Drinks Market by Application (Hypermarket & Supermarket, Food & Drink Specialists & Convenience Stores), by Product Type (Alcoholic Drinks & Non-alcoholic Drinks), Business scope and Outlook – Estimate to 2028". for more information or any query mail at sales@htfmarketreport.com At last, all parts of the Global (United States, European Union and China) Frozen Drinks Market are quantitatively also subjectively valued to think about the Global just as regional market equally.
→ Google Traduction
General Mills is setting all-time highs like it''s going out of style.
→ Google Traduction
NORTHAMPTON, MA / ACCESSWIRE / September 23, 2022 / Gilead Sciences For Dr. Javier Cortes, being a breast cancer researcher isn''t just a profession - it''s a calling. As the head of the International Breast Cancer Center (IBCC) in Madrid and Barcelona, he has made it not only his life''s work but also his personal mission to help improve the lives of the people he treats every day. As the oncology community gathers for the European Society of Medical Oncology (ESMO) Congress in Paris, we sat down with Javier to learn why scientific exchange and the gathering of researchers is so necessary, both for people living with cancer and for those who work in the field. Q: Your commitment to research, in addition to providing care to people living with cancer, has spanned your career. Why do you feel so strongly about balancing clinical care with scientific discovery? The exchange of science is what you might call a lynchpin for medicine. It''s key to advancing research that has the best chance to be successful and to improve the lives of the people we treat.
→ Google Traduction
Robert Stimpson has beaten 97% of his peers over the last 3 years. Stimpson is the co-CIO at Oak Associates Funds, which manages $1.4 billion in assets. He shared with Insider 8 stocks he likes for the next 3-5-year period. At the helm of the River Oak Discovery fund ( RIVSX ), Robert Stimpson has beaten 97% of his peers over the last three years, and 95% over the last half-decade, according to Morningstar data. This year, his Live Oak Health Sciences fund ( LOGSX ) is outpacing 97% of similar funds, and 93% over the last one-year period. But the outperformance hasn’t come from Stimpson frequently shifting his sails to benefit from any shorter-term wind that comes along, or from diversifying his funds for the sake of diversification. For example, he’s stayed away from energy firms despite their outperformance this year and last, because he believes the price of oil will face long-term downward pressure due to the political interests of the US. “We are not afraid to be naked those sectors of the economy we don’t feel are going to be beneficial to own long-term,” said Stimpson, the co-CIO and portfolio manager at Oak Associates Funds, which manages $1.4 billion in assets.
→ Google Traduction
Merck & Company found using ticker (MRK) have now 20 analysts in total covering the stock. The consensus rating is ''Buy''. The target price ranges between 125 and 85 with the average target price sitting at 100.85. With the stocks previous close at 84.53 this is indicating there is a potential upside of 19.3%. The day 50 moving average is 88.99 and the 200 moving average now moves to 84.66. The company has a market cap of $221,687m. Company Website: https://www.merck.com [stock_market_widget type="chart" template="basic" color="green" assets="MRK" range="6mo" interval="1d" axes="true" cursor="true" api="yf"] The potential market cap would be $264,488m based on the market concensus. Merck & Co. operates as a healthcare company worldwide. It operates through two segments, Pharmaceutical and Animal Health. The Pharmaceutical segment offers human health pharmaceutical products in the areas of oncology, hospital acute care, immunology, neuroscience, virology, cardiovascular, and diabetes, as well as vaccine products, such as preventive pediatric, adolescent, and adult vaccines.
→ Google Traduction
Chartwell Investment Partners, an asset management company, released its second quarter 2022 investor letter. A copy of the same can be downloaded here. For the second quarter, Chartwell-managed accounts fell in line with their respective index benchmarks, however, the Chartwell Dividend Model outperformed by a significant margin versus its benchmark. Go over the fund’s top […]
→ Google Traduction
Someone with a lot of money to spend has taken a bearish stance on General Mills (NYSE: GIS ). And retail traders should know. We noticed this today when the big position showed up on publicly available options history that we track here at Benzinga. Whether this is an institution or just a wealthy individual, we don''t know. But when something this big happens with GIS, it often means somebody knows something is about to happen. So how do we know what this whale just did? Today, Benzinga ''s options scanner spotted 15 uncommon options trades for General Mills. This isn''t normal. The overall sentiment of these big-money traders is split between 26% bullish and 73%, bearish. Out of all of the special options we uncovered, 5 are puts, for a total amount of $200,745, and 10 are calls, for a total amount of $402,201. What''s The Price Target? Taking into account the Volume and Open Interest on these … Full story available on Benzinga.com
→ Google Traduction
Major players in the non-dairy yogurt market are Hain Celestial, Danone, General Mills Inc. , Stonyfield Farm Inc. , Daiya Foods Inc. , Whitewave Foods Company Inc, COYO Pty Ltd. , Chobani LLC, Valio Ltd, Nestlé SA, Good Karma Foods Inc. Major players in the non-dairy yogurt market are Hain Celestial, Danone, General Mills Inc. , Stonyfield Farm Inc. , Daiya Foods Inc. , Whitewave Foods Company Inc, COYO Pty Ltd. , Chobani LLC, Valio Ltd, Nestlé SA, Good Karma Foods Inc.
→ Google Traduction
Major players in the oatmeal market are Nature’s Path Foods Inc, Nestle SA, General Mills Inc, Post Holdings Inc (Weetabix ltd), La Crosse Milling Company, Cargill Incorporated, Kellogg Company, PepsiCo Inc (The Quaker Oats Company), Bob’s Red Mill Natural Foods, Bagrrys India Ltd and Marico Limited. Major players in the oatmeal market are Nature’s Path Foods Inc, Nestle SA, General Mills Inc, Post Holdings Inc (Weetabix ltd), La Crosse Milling Company, Cargill Incorporated, Kellogg Company, PepsiCo Inc (The Quaker Oats Company), Bob’s Red Mill Natural Foods, Bagrrys India Ltd and Marico Limited.
→ Google Traduction
Gilead Sciences will underperform the market during bull markets due to its inability to grow rapidly like some companies. Click here to see why I give a hold rating to GILD.
→ Google Traduction
Morgan Stanley cut the price target for NIKE, Inc. (NYSE: NKE ) from $149 to $129. NIKE shares fell 0.6% to $99.20 on Thursday. B of A Securities raised the price target on General Mills, Inc. (NYSE: GIS ) from $74 to $81. General Mills shares rose 1.2% to $80.70 on Thursday. Truist Securities cut Biogen Inc. (NASDAQ: BIIB ) price target from $270 to $265. Biogen shares fell 1% to $197.30 on Thursday. Baird lowered the price target on Cognizant Technology Solutions Corporation (NASDAQ: Full story available on Benzinga.com
→ Google Traduction
Gilead Sciences, Inc. today announced a new public-private initiative with the Partnership for Health Advancement in Vietnam (HAIVN), a collaboration between Brigham and Women’s Hospital, Harvard Medical School and Beth Israel Deaconess Medical Center. This multi-year initiative will have a phased approach to help address barriers that limit viral hepatitis diagnosis and care at primary healthcare
→ Google Traduction
Stocks spent most of Wednesday in positive territory, but went on a roller-coaster ride after the Federal Reserve, as expected, issued its third straight 75 basis point rate hike. SEE MORE Hedge Funds'' 21 Top Blue-Chip Stocks to Buy Now The Fed''s rate hike sparked plenty of chatter among Wall Street''s experts, with the main focus on what the central bank plans to do next. Today''s move brought the Fed''s benchmark federal funds rate to between 3.0% and 3.25%, with projections from the 19 voting members of the Federal Open Market Committee (FOMC) targeting a range of 4.25% and 4.5% by year''s end – a half-percentage point higher than where it was in June. Doing the math, that means rates need to rise another 1.25% over the central bank''s remaining two meetings (in November and December). "Today we heard and saw more of the same, and the market shouldn''t be too surprised given the Fed and its officials telegraphed that more big hikes were in the cards for the foreseeable future," says Mike Loewengart, head of model portfolio construction at Morgan Stanley. "The market seems to have hoped beyond hope that they would hear some reference to an end to rate hikes on the horizon, but that''s certainly not what we got today." Sign up for Kiplinger''s FREE Investing Weekly e-letter for stock, ETF and mutual fund recommendations, and other investing advice.
→ Google Traduction
Stocks fell in volatile trading Wednesday after the Federal Reserve raised rates by three-quarters of a point and forecast more sizable rate hikes in its fight against inflation, actions widely expected by traders. The Dow Jones Industrials tumbled 522.45 points, or 1.7%, to wrap up Wednesday trading at 30,183.78. The S&P 500 let go of 66 points, or 1.7%, to 3,789.93. The NASDAQ Composite fell 204.86 points, or 1.8%, to 11,220.19. With the S&P 500 down more than 8% in the past month and 18% for 2022 heading into Wednesday’s Fed actions, stocks were already pricing in an aggressive tightening campaign by the Fed that could push the economy into a recession. The Fed raised rates by 0.75 percentage point, or 75 basis points, as was widely expected, and said it expects its so-called terminal rate to reach 4.6% to fight persistently high U.S. inflation. That’s the rate at which the central bank will end its tightening regime. The central bank also indicated that it plans to stay aggressive, hiking rates to 4.4% by next year.
→ Google Traduction
General Mills (GIS) shares rose on Wednesday after the company posted a beat-and-raise quarter. Read more.
→ Google Traduction
Gilead Sciences, Inc. (Nasdaq: GILD) today announced the completion of the previously announced transaction to acquire MiroBio, a privately held U.K.-based biotechnology company focused on restori…
→ Google Traduction
FOSTER CITY, Calif.--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq: GILD) today announced the completion of the previously announced transaction to acquire MiroBio, a privately held U.K.-based biotechnology company focused on restoring immune balance with agonists targeting immune inhibitory receptors, for approximately $405 million in cash. The acquisition provides Gilead with MiroBio’s proprietary discovery platform and entire portfolio of immune inhibitory receptor agonists. MiroBio’s lead
→ Google Traduction
Gilead Sciences (NASDAQ: GILD ) has outperformed the market over the past 15 years by 1.63% on an annualized basis producing an average annual return of 7.98%. Currently, Gilead Sciences has a market capitalization of $80.93 billion. Buying $100 In GILD: If … Full story available on Benzinga.com
→ Google Traduction
General Mills (GIS) is scheduled to announce FQ1 earnings results on Wednesday, September 21st, before market open.The consensus EPS Estimate is $1.00 (+1.0% Y/Y) and the consensus…
→ Google Traduction
General Mills (NYSE: GIS ) is set to give its latest quarterly earnings report on Wednesday, 2022-09-21. Here''s what investors need to know before the announcement. Analysts estimate that General Mills will report an earnings per share (EPS) of $1.00. General Mills bulls will hope to hear the company to announce they''ve not only beaten that estimate, but also to provide positive guidance, or forecasted growth, for … Full story available on Benzinga.com
→ Google Traduction
Here is what analysts expect when these three companies post their quarterly results late Tuesday or first thing Wednesday morning.
→ Google Traduction
Learn More about NanoViricides, Inc. by gaining access to the latest research report As cases of the monkeypox virus continue to grow, the race is on for a way to fight this once-rare disease. Since the first reports of monkeypox infection in the United States started popping up in May, cases have now been reported in all 50 states for a total of over 23,000 new infections . In response to that rapid spread, NanoViricides Inc. (NYSEAMERICAN: NNVC) wants to speed up the timeline on the development of its novel antiviral platform to treat the monkeypox virus. Here’s the company’s plan for bringing its monkeypox drug development platform to clinical trials sooner. NanoViricides’s Rapid Drug Development Program For Monkeypox Antiviral Having already begun drug development of NV-387-T, its monkeypox drug candidate, NanoViricides reports that it’s optimistic it can speed up the process to move the antiviral into human clinical trials quickly. Its reasons for that optimism are twofold. First, the active ingredient tecovirimat has already been approved by the Food and Drug Administration (FDA) as a smallpox treatment.
→ Google Traduction
Finding penny stocks with buy ratings is becoming increasingly difficult. The higher interest rates go, the more risk-averse the markets become. That means that penny stocks, which are riskier by nature, are finding their ratings declining in the current environment. A few months ago penny stocks with buy ratings that were doing well suddenly found themselves downgraded to a hold rating or worse. That indicates that the already risky world of penny stocks is becoming riskier still. So, it should come as little surprise that investors are seeking penny stocks with buy ratings through early September. Those equities should have more stability and better chances of price appreciation in what is usually a tough month for equities. That said, let’s dive deeper into those shares. NNDM Nano Dimension $2.50 HYRE HyreCar $1.28 MNKD MannKind $3.56 TBLT ToughBuilt Industries $2.37 AGEN Agenus $2.36 NBEV NewAge $0.09 CORZ Core Scientific $1.90 Nano Dimension (NNDM) Source: Spyro the Dragon / Shutterstock.com Nano Dimension (NASDAQ: NNDM ) stock carries a buy rating and plenty of upside.
→ Google Traduction
Traders work on the floor of the New York Stock Exchange during the afternoon trading session on September 13, 2022 in New York City. Michael M. Santiago | Getty Images News | Getty Images S&P 500 futures were little changed Sunday evening after the major averages posted their worst week since June and ahead of this week’s two-day Federal Reserve meeting. Broad market index futures contracts were flat in pre-market trading. Dow Jones Industrial Average futures rose 0.1%, while Nasdaq 100 futures declined 0.1%. Stocks fell on Friday as investors reacted to a hotter-than-expected inflation report and a gloomy warning from FedEx about the “significantly deteriorating” global economy. The Dow Jones Industrial Average fell 139 points, while the Standard & Poor’s lost 0.7% and the Nasdaq Composite fell 0.9%. Investors are focused on the Federal Reserve’s two-day meeting, which begins on Tuesday. The central bank is expected to raise interest rates by another three-quarters of a point, although investors are also watching for guidance on corporate earnings ahead of the start of the next reporting season in October. “With the S&P 500 hovering below the critical 3900 level and the 10-year Treasury yield approaching more than 3.5%, the Fed’s sensitive two-year Treasuries shrug off 3.9%, suggesting that the Fed’s aggressive campaign to kill Crosby, chief global strategist at LBL Financial, “Inflation needs to be taken seriously.” The canary in the coal mine may not have died yet, but it is probably struggling to breathe.
→ Google Traduction
Here are the key items to focus on prior to General Mills'' upcoming earnings release. Click here for a full preview and investment analysis.
→ Google Traduction
FedEx (FDX), Costco (COST), Darden Restaurants (DRI), KB Home (KBH), Lennar (LEN) and General Mills (GIS) are scheduled to report earnings next week.
→ Google Traduction
The European drug regulator''s human medicines committee had recommended a new dosage strength for Gilead Sciences'' (GILD) HIV drug Biktarvy and an extension of its indication
→ Google Traduction
(RTTNews) - Gilead Sciences Inc. (GILD) announced Friday that its unit Kite''s CAR T-cell Therapy Yescarta (axicabtagene ciloleucel) has received a positive opinion from the European Medicines Agency''s Committee for Medicinal Products for Human Use or CHMP for use in second-line diffuse large B-cell lymphoma and high-grade B-cell lymphoma.
→ Google Traduction
– Positive Opinion Based on Landmark ZUMA-7 Study in Which 41% of Patients Demonstrated Event-Free Survival at Two Years versus 16% for Standard of Care - Kite, a Gilead Company (NASDAQ: GILD ), today announces that the European Medicines Agency (EMA) Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion for Yescarta ® (axicabtagene ciloleucel) for adult patients with diffuse large B-cell lymphoma (DLBCL) and high-grade B-cell lymphoma (HGBL) that relapses within 12 months from completion of, or is refractory to, first-line chemoimmunotherapy. If approved, Yescarta will be the first Chimeric Antigen Receptor (CAR) T-cell therapy approved for patients in Europe who do not respond to first-line treatment. Although 60% of newly diagnosed LBCL patients will respond to their initial treatment, 40% will relapse or will not respond and need 2nd line treatment. "At Kite, we are committed to bringing the curative potential of cell therapy to the world, and changing the way cancer is treated," said Christi Shaw, CEO, Kite. "Today''s positive CHMP opinion brings us a step closer to utilizing cell therapy earlier in the treatment journey, potentially transforming the standard of care for the most common and aggressive form of non-Hodgkin lymphoma." The European Commission will review the CHMP opinion, and a final decision on the marketing authorization is expected in the coming months. "For people with DLBCL and HGBL who do not respond to first-line treatment or have an early relapse, outcomes are often poor and there are limited curative treatment options for these patients," said Marie José Kersten, Professor of Hematology at Amsterdam University Medical Centers, Amsterdam. "If approved, axicabtagene ciloleucel may offer a new standard of care for patients with relapsed or refractory DLBCL and HGBL.
→ Google Traduction
Gilead Sciences Inc. (NASDAQ:GILD) shares, rose in value on Thursday, September 15, with the stock price down by -0.51% to the previous day’s close as strong demand from buyers drove the stock to $64.85. Actively observing the price movement in the recent trading, the stock is buoying the session at $65.18, falling within a range … Read This First Before You Buy Gilead Sciences Inc. (NASDAQ: GILD) Stock Read More »
→ Google Traduction
In a victory for Gilead, Brazilian antitrust authorities dismissed a complaint about the company''s prices for a hepatitis C drug.
→ Google Traduction
In a victory for Gilead, Brazilian antitrust authorities dismissed a complaint alleging the company charged “abusive” prices for a hepatitis C treatment.
→ Google Traduction
Merck & Company found using ticker (MRK) now have 20 analysts covering the stock with the consensus suggesting a rating of ''Buy''. The target price ranges between 125 and 85 calculating the mean target price we have 100.85. Given that the stocks previous close was at 85.59 this is indicating there is a potential upside of 17.8%. The day 50 moving average is 89.93 and the 200 day moving average is 84.25. The market cap for the company is $220,269m. You can visit the company''s website by visiting: https://www.merck.com [stock_market_widget type="chart" template="basic" color="green" assets="MRK" range="6mo" interval="1d" axes="true" cursor="true" api="yf"] The potential market cap would be $259,541m based on the market concensus. Merck & Co. operates as a healthcare company worldwide. It operates through two segments, Pharmaceutical and Animal Health. The Pharmaceutical segment offers human health pharmaceutical products in the areas of oncology, hospital acute care, immunology, neuroscience, virology, cardiovascular, and diabetes, as well as vaccine products, such as preventive pediatric, adolescent, and adult vaccines.
→ Google Traduction
Gilead Sciences, Inc. (NASDAQ:NASDAQ:GILD) Baird 2022 Global Healthcare Conference September 14, 2022 09:30 AM ET Company Participants Johanna Mercier - Chief Commercial Officer Conference…
→ Google Traduction
General Mills with ticker code (GIS) now have 17 analysts in total covering the stock. The consensus rating is ''Hold''. The target price ranges between 81 and 57 with a mean TP of 73.06. Now with the previous closing price of 76.15 this is indicating there is a potential downside of -4.1%. The 50 day moving average now sits at 75.97 and the 200 day MA is 69.98. The market cap for the company is $44,291m. Company Website: https://www.generalmills.com [stock_market_widget type="chart" template="basic" color="green" assets="GIS" range="6mo" interval="1d" axes="true" cursor="true" api="yf"] The potential market cap would be $42,494m based on the market concensus. General Mills manufactures and markets branded consumer foods worldwide. The company operates in five segments: North America Retail; Convenience Stores & Foodservice; Europe & Australia; Asia & Latin America; and Pet. It offers ready-to-eat cereals, refrigerated yogurt, soup, meal kits, refrigerated and frozen dough products, dessert and baking mixes, bakery flour, frozen pizza and pizza snacks, snack bars, fruit and salty snacks, ice cream, nutrition bars, wellness beverages, and savory and grain snacks, as well as various organic products, including frozen and shelf-stable vegetables.
→ Google Traduction
- ← précédent
- 1
- 2
- 3
- …
- 28
- 29
- suivant →